Radiopharmaceuticals

Radioligand therapies and nuclear medicine approaches for targeted cancer treatment and diagnostic imaging.

Companies

Pipeline Drugs

Key People

Radiopharmaceuticals Pipeline (29 drugs)

Preclinical: 4Discovery: 4Phase 1/2: 4Research: 3Pre-clinical: 3Phase 2/3: 3Phase 1: 2Phase 2: 2Launched: 1Discovery/Pre-clinical: 1Pre-clinical/Development: 1Approved: 1

Drug	Company	Indication	Phase	Status
Lecanemab	BioArctic	Alzheimer's Disease	Launched	Active (Commercial)
BAN2802	BioArctic	Parkinson's Disease	Phase 1	Active
BAN2401	BioArctic	Alzheimer's Disease	Preclinical	Active
Stem Cell Program	BioArctic	ALS	Research	Active
NTRX-07	NeuroTherapia	Alzheimer's Disease	Phase 2	Active
MVD-1 (SANA)	Eolo Pharma	Obesity	Phase 1	Active
Eolo40 NCE	Eolo Pharma	ALS	Discovery	Active
NF-kB inhibitor	Eolo Pharma	Alzheimer's Disease	Discovery	Active
KIWI Platform	ni2o	Alzheimer's Disease	Pre-clinical	Active
Platform Extension	ni2o	Parkinson's Disease, ALS	Pre-clinical	Active
Daiichi-Sankyo Co-development Program	Meddenovo Drug Design	Undisclosed	Discovery/Pre-clinical	Active
PickASO Project	DIVERCHIM CDMO	Therapy to activate autophagy (via ASO)	Pre-clinical/Development	Active
Clinical Endpoint Solutions	Vitalograph	Various Respiratory Conditions	Phase 2/3	Active
Respiratory In-Clinic Monitoring	Vitalograph	COPD, Asthma, etc.	Phase 2/3	Active
Home Respiratory Monitoring	Vitalograph	Chronic Respiratory Diseases	Phase 2/3	Active
Alzheimer's Disease Program	Selonterra	Alzheimer's Disease (APOE4)	Preclinical	Active
Parkinson's Disease Program	Selonterra	Parkinson's Disease (SNCA A53T, LRRK2 G2019S)	Preclinical	Active
ALS/FTD Program	Selonterra	ALS/Frontotemporal Dementia (C9orf72)	Research	Active
Familial Alzheimer's Program	Selonterra	Alzheimer's Disease (Familial mutations)	Research	Active
Cell-Safe™ for Islet Transplantation	Cell-Safe Life sciences	Type 1 Diabetes	Pre-clinical	Active
Lecanemab (Leqembi®)	bioarctic-ab	Early Alzheimer's Disease	Approved	Commercial
BAN0805	bioarctic-ab	Parkinson's Disease	Preclinical	Research
Anti-alpha-synuclein Oligomer mAb	bioarctic-ab	Multiple System Atrophy (MSA)	Discovery	Research
Undisclosed Program	bioarctic-ab	ALS	Discovery	Research
VMT-α-NET	Perspective Therapeutics	Neuroendocrine Tumors & other SSTR2+ tumors	Phase 1/2	Cohort 2 completed, Cohort 3 DLT recruited & under evaluation
VMT01/02 (Monotherapy)	Perspective Therapeutics	Melanoma (MC1R+)	Phase 1/2	Enrolling (3.0 mCi)
VMT01/02 (Combination with Nivolumab)	Perspective Therapeutics	Melanoma (MC1R+)	Phase 1/2	Enrolling (3.0 mCi)
PSV359	Perspective Therapeutics	Multiple Solid Tumors (FAP-α+)	Phase 1/2	Enrolling (5.0 mCi)
Radspherin	Oncoinvent	Peritoneal Metastases from Ovarian Cancer	Phase 2	Active